about
Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarrayFully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancersPrognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.Neoadjuvant therapy for gastroesophageal adenocarcinomaKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transferPreoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.Validation of an appropriate reference gene for normalization of reverse transcription-quantitative polymerase chain reaction data from rectal cancer biopsies.Reverse transcription-quantitative polymerase chain reaction: description of a RIN-based algorithm for accurate data normalization.Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyAntibody targeting of claudin-1 as a potential colorectal cancer therapy.High fragmentation characterizes tumour-derived circulating DNA.Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).The role of the FOLFIRINOX regimen for advanced pancreatic cancer.Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie DigestivSpecific extracellular matrix remodeling signature of colon hepatic metastases.Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialPredictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental modelSafety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer.Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis.MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy.Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
P50
Q24675853-33357626-C020-4EFB-88D3-080A3BBFCAD2Q24792155-6AA74162-A796-4B7D-967D-A506EEE9213EQ24812583-1A74EC4F-C4E9-4CFB-B104-831E8FB21DF9Q26746147-E736EFFF-87E7-4EC4-805F-E8E7726072E7Q27851422-D207503E-6599-4F5C-BD21-8CDBA43DBD67Q28481420-6ADC3E6E-DDFB-4120-9BA2-18FA59B670E3Q30651639-FADDEA36-7583-422A-A596-25E70DC3AEB7Q33230069-CEB5517F-1ECF-4FC5-9BF8-3AF1E4B231E8Q33379811-A4996313-59EE-4459-ACBA-B5AEE141419AQ33387763-1C2A2F4B-D52D-4A92-8EC3-8CA34D10AC04Q33389592-FA28C7B5-31E4-4C23-9D87-2CA4F57FA5DDQ33416233-812E56D4-F68B-4495-AA2A-12872662809EQ33430530-48152AB3-E8F2-42F6-B973-26A4E2B6057FQ33507171-E2A9EF63-C169-4B97-8CC0-08B8FE8C7303Q33850900-CAC878F4-59D3-4255-A53B-F49AE765F06BQ34016528-4F4E23F3-0A32-4B5C-8D4F-9E01C65D23B0Q34308370-2AB723D5-34D8-4255-9E29-6252405D6B4EQ34323833-647C32EC-FE23-4242-AE94-AF97787E8BEEQ34646032-28F8F3AB-52D7-4936-A13B-9467E9BF9EDAQ34665199-56BEC6A7-93EB-41DF-ABC3-40D12CBB26CEQ34984735-F0E34C02-A083-4BAC-947F-4EEF7E0C6454Q35127938-0A746B23-13E3-43E1-BDA3-01AD4A18018BQ35319001-44995DD1-3E1A-40A9-A6C9-2100A0DF46F4Q35828693-77241A0F-1B23-4A6B-B91D-AC7E79365B26Q36383473-870BE9D8-9AD9-4FBA-86B1-0169B050A4B5Q36616040-E8B4A0EC-DA7D-46AF-834A-E96B9058F732Q36620441-AA35CB54-E62A-4B16-ACBA-32E2CB13978BQ36648908-1DB2FF6D-32CC-4B52-811A-944027A0E7E4Q36671593-09043E36-4CC0-47EF-9D59-2A06B7BAAF6EQ36839008-3A9C2F7D-1718-46E4-A4AA-3F844549C6FBQ36865058-469A5893-590A-4818-81FF-4D5BCC2AD827Q36964986-2CDACFD0-3461-41E2-BEDD-C676E2EDB046Q37510393-D667D3F2-6095-45B8-A854-AEAAFE0ED969Q37696246-E96A6AD1-51EB-4C76-9D50-C65D45A926DFQ37726604-3FB8B5FB-AF1A-4894-8391-5552FD9021C3Q37995997-E4003FCD-8D52-4D1E-A4F6-BAA5383F1F5AQ38005946-5C970E47-8FD1-454E-9D41-6A5DFE7DDD32Q38037811-7532E896-DB8E-4FD2-A8F4-43802763CA9AQ38375059-0A09DEB3-9E9F-4CD7-9B4B-247D4DBF5DA6Q38385410-4BB3FC30-92C0-4C20-BF32-3F001F5E5D52
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marc Ychou
@ast
Marc Ychou
@en
Marc Ychou
@es
Marc Ychou
@nl
type
label
Marc Ychou
@ast
Marc Ychou
@en
Marc Ychou
@es
Marc Ychou
@nl
prefLabel
Marc Ychou
@ast
Marc Ychou
@en
Marc Ychou
@es
Marc Ychou
@nl
P106
P21
P31
P496
0000-0001-7378-9469